Back to search results

Observational Study of Semaglutide and Brown Fat Activity in Obesity

This observational study is looking into how semaglutide, a medication used for weight loss, affects 'brown fat' (brown adipose tissue or BAT) activity in people with obesity. Brown fat helps the body burn calories and may play a role in weight loss. Researchers want to understand if semaglutide activates brown fat, which could explain how it helps people lose weight. You would be eligible if you are starting semaglutide for weight loss, are over 18, and are male or a post-menopausal female. The study will measure changes in your supraclavicular (above the collarbone) temperature, how much food you eat, and your resting metabolism over 20 weeks to see the effects of semaglutide.

Study design
This is an observational study with 20 participants. It is not specified if it is blinded or randomized.
What's involved
You would have measurements taken before starting semaglutide, then again at 2-4 weeks and 18-20 weeks after starting the medication. These measurements include infrared thermography images of your brown fat.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 20 weeks, which is when the primary endpoints are measured.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05419726

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Recruiting
Not specifiedAges 18+Observational
University of California, Los Angeles
~20 participants
Updated 2025-05-11 on ClinicalTrials.gov
What's tested:Semaglutide Injectable Product (not provided by the study)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
change in supraclavicular temperature with cold exposure
Measured over 20weeks
+2 more outcomes measured

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Preethi Srikanthan, MD · PRINCIPAL_INVESTIGATOR · Principal Investigator

Who to contact

Preethi Srikanthan, MD
[email protected]
310-825-7922
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects scheduled to start semaglutide for weight loss (drug not provided by or paid for by the study)
\>18 years of age and willing to participate
Male or post-menopausal females

Exclusion

History of prior neck surgery and /or neck irradiation
Use of beta blocker agents
Use of any other glucose lowering medication
History of neuropathic disorders (e.g. diabetic neuropathy)
Diabetic patients
Individuals without normal thyroid function
Individuals with cancer
Any significant chronic disease or renal, hepatic or endocrine disease
Current smokers
Inability of patient to provide consent either for medical reasons or psychiatric reasons

What this trial measures

  • change in supraclavicular temperature with cold exposure20weeks

    delta temperature

  • change in caloric intake20weeks

    caloric intake

  • basal metabolic rate20 weeks

    basal metabolic rate (ml O2/min or joule per hour per kg body mass)